Taking a step back, its interesting to review the history of the Endosomal Escape Trap technology. Phylogica launched the EET in June 2013 at the American Peptide Symposium and the Next Generation Protein Therapeutics Summit. Although heralded as a breakthrough in peptide discovery its big splash on the world stage appeared to be no more than a ripple.
What were we expecting to happen? I, at least, thought that it would generate some level of excitement given the critical importance of endosomal escape to the intracellular delivery of therapeutics. It was the biologics equivalent to Jules Verne's Journey to the Centre of the Earth.
There was, however, no applause, no headlines of a medical breakthrough and certainly no rush by Big Pharma to sign collaboration agreements.
It was an interesting concept but undoubtedly what Big Pharma required was data. Phylogica needed to demonstrate that the technology could deliver phylomer candidates which could plug-n-play with existing therapies.
If the data is now available, it almost certainly is in the hands of Janssen. What I find interesting is that Phylogica has not stopped talking about the EET. In fact, they will be talking about it again at Tides. This time, however, Watt will make his presentation in a session titled Endosomal Escape, Peptide Targeting and Intracellular Delivery. Its as if, within the space of 12 months, the use of the term 'endosomal escape' has become a meme, so often repeated that its forged its own classification.
I can only wonder if there has been a breakthrough in the intracellular delivery of biologics; a paradigm shift in medical science. If so, Phylogica could well be at the epicentre.
PYC Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)